[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Catalyst Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100559503",false,"NCT06564974","Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT","Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy [SUpplemental Patient dMd assessMents Investigating ouTcomes (SUMMIT)]","DMD-001 SUMMIT","Inclusion Criteria:\n\n1. Patient or parent\u002Flegal guardian is willing and able to provide written informed consent once the nature of the registry has been explained and prior to the start of any registry-related procedures.\n2. Patient and\u002For parent\u002Fguardian are willing and able to complete QoL questionnaires.\n3. Male patients at least 2 years old.\n4. Confirmed diagnosis of DMD (via genetic testing or muscle biopsy with absent dystrophin staining to anti- dystrophin antibodies 3, 1, or 2, or dystrophin immunohistochemistry or western blot).\n5. Patient has a current, active prescription for, or is on, AGAMREE®.\n\nExclusion Criteria:\n\n1\\. Any contraindication to AGAMREE® or medical condition, which, in the opinion of the Investigator, would affect registry participation, performance, or interpretation of registry assessments.","MALE","2 Years",{"count":19,"type":20},250,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by standardized patient-reported outcome measures (QoL questionnaires) in male patients aged 2 years and older with Duchenne muscular dystrophy (DMD).",[25],"Duchenne Muscular Dystrophy",[25,27,28,29,30,31],"Neuromuscular","AGAMREE®","Vamorolone","DMD","Muscular Dystrophy","RECRUITING","2026-02-23",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":36},"2024-09-25",{"date":40,"type":20},"2032-02",{"name":42,"class":43},"Catalyst Pharmaceuticals, Inc.","INDUSTRY",27,""]